Issue link: https://www.e-digitaleditions.com/i/1515319
The industry organizations page of the Inhalation website provides descriptions and contact information for cross-industry organizations and groups that present educational conferences and workshops. 32 February 2024 Inhalation can be rapidly adapted to new pharma compounds and thera- pies," said Stephen Knowles, IDC´s Managing Director. Berry introduces breath- actuated inhaler EVA NSV ILLE, INDI A NA— Berr y ha s introduced a ne w bre at h-ac t u ated, mu lt i- dose inhaler named the PneumoHaler. Pharmiweb.com described a variety of its features, including actuation at a very low airflow rate, readily achievable by most patients. e internal mechanism of the Pneu- moHaler engages only when a patient opens the mouthpiece cap for inhalation, rather than being compressed at all times, which could result in performance dete- rioration over time. The Pneu- moHaler can be supplied with or without a priming feature. e new breath-actuated inhaler can be adapted for a variety of valves and canisters, making it compatible with a wide range of treatments and enabling it to be tailored to customer requirements. "e Pneu- moHaler has been designed pri- marily with patient ease in mind," explained Alan Quemeneur, Global Sales Director, Berry Healthcare. "Equally important, it is readily available and easy to adapt to indi- vidual drug requirements, offer- ing pharmaceutical companies speed-to-market." AstraZeneca receives approval in India C A M B R I D G E , U N I T E D KINGDOM—AstraZeneca India announced it has received approval f rom Ind ia's C ent ra l Dr u g s Standard Control Organisation (CDSCO) to market its inhala- tion aerosol; a triple combination of budesonide (160 mcg), glyco- pyrrolate (9 mcg) and formoterol fumarate (4.8 mcg). e pressur- ized metered dose inhaler (pMDI) is recommended for the treatment and maintenance of patients with chronic obstructive pulmonary disease (COPD), according to Expresspharma.in. "COPD is prob- pressurized metered dose inhalers (pMDIs). e new pMDIs will utilize valves and actuators from Recipharm's Bespak ® brand as well as a new generation of low global warming potential (GWP) pro- pellants. A company news release noted the companies will work to ensure the fastest possible pathway to market for customers. e first formulations will utilize Koura's Zephex ® HFA-152a, a sustainable medical propellant, to significantly reduce a device's overall carbon footprint. In addition, Recipharm is able to offer its customers a choice of green propellants to use in pMDIs. In 2023, the company announced its collaboration with Honeywell to develop pMDIs fea- turing the Honeywell Solstice ® Air (HFO-1234ze(E)) cGMP propel- lant. Recipharm is also expanding the commercial-scale pMDI manu- facturing capabilities at its Holmes Chapel, UK site. Hovione and IDC develop nasal delivery devices LISBON, PORTUGAL—Hovi- one announced the expansion of its nasal drug delivery capabilities with the addition of two active nasal delivery devices, developed in partnership with Industrial Design Consultancy (IDC). One is a single- use device; the other provides multi-dose delivery. A company news release noted both devices use standard capsules and filling equipment so they have the potential to simplify drug prod- uct development and manufac- turing. Hovione will offer the new devices on an exclusive basis as part of its integrated offer for nasal drug development and manufac- turing. "By combining Hovione's capabilities in pharmaceutical development, formulation and manufacturing with IDC's device development expertise, this part- nership offers customers a nasal powder delivery solution which ably an underprioritized disease around the world," said Sanjeev Panchal, Country President and Managing Director, AstraZeneca India. "In India, [the] government has already demonstrated its intent to manage COPD better by includ- ing it in [the] National Programme for Prevention and Control of Can- cer, Diabetes, Cardiovascular dis- eases and Stroke (NPCDCS). is approval is also a strong example of innovative drug delivery technique that can target a common thera- peutic challenge thereby reducing mortality as well as [the] overall COPD disease burden." Meggle introduces new lactose-based excipient WASSERBURG, GERMANY— Meggle has launched InhaLac ® 145 as the latest addition to its range of crystalline, lactose-based excipients specifically designed to support dry powder inhaler (DPI) formulations. A company news release explained that specific carrier lactose excip- ient particle size distributions (PSDs) are needed to allow for- mulations to be tailored precisely to target applications and extract opti- mum performance from inhaler devices. With its mean particle size of 35 µm, the new excipient bridges the small gap between the DPI milled lactose monohydrates InhaLac 140 (50 µm) and InhaLac 150 (24 µm). e InhaLac 145 PSD profile ensures approximately 10% of particles below 5 µm, retaining the typical flow and surface char- acteristics of milled lactose with irregular particle shapes. CALENDAR Please visit the industry organiza- tions page of the Inhalation website to find descriptions and contact information for cross- industry organizations and groups that present educational conferences and workshops. https://www.inhalationmag.com/ industry-organizations INDUSTRY NEWS continued from page 8